ANIK today
$13.81-$0.14 (-1.00%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourBullish
15 minStrong Bullish
5 minSymmetric Triangle
Daily trend turns up above $22.88
Key levels
Resistance$16.27
Resistance$14.58
Support$13.33
Support$11.92
Latest news & SEC filings
EarningsAnika Therapeutics lifts 2026 outlook after Q3 2026 report
EarningsAnika Therapeutics holds Q3 2026 earnings call
SEC FilingAnika Therapeutics, Inc. filed a report on a major company event (Form 8-K)
GuidanceAnika Therapeutics lifts FY2026 sales guidance to $119.588M-$124.101M
EarningsAnika Therapeutics posts $0.29 adjusted per-share profit, $30.594M in quarterly revenue
All ANIK news →About Anika Therapeutics
Anika Therapeutics develops hyaluronic acid-based medical products for orthopedics, focused on osteoarthritis pain management and regenerative solutions. Its main products include injectable viscosupplements for joint pain, a tendon repair scaffold, and cartilage repair therapies. The company sells directly and through distributors and licensing partners in the United States and internationally, serving clinicians, hospitals, and surgery centers.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
Anika Therapeutics, Inc. (ANIK)
What Is the Price Target for ANIK?
SEPT Low Target
$21.00
SEPT Mid Target
$22.00
SEPT High Target
$23.00
Analyst Consensus
$22.00
Is ANIK a Buy or Sell Right Now?
Thesis
- •Revenue growing -5.9% YoY with DECLINING trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ANIK.
Start Free Trial →Is ANIK Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$21.76
20
Moat Score
NONE
5/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with ANIK?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Griffin Stephen D. | director officer | Sale | 3,769 | $54K | Jun 3, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ANIK Growth Story
Revenue YoY
-5.9%
3yr Revenue CAGR
-0.3%
EPS Growth YoY
80.16%
FCF Growth YoY
287.1%
Revenue Trend
DECLINING
Dark Pool Trades for ANIK
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ANIK, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:53:44 | $14.12 | 4,000 | $$56K | BUY |
| 21:00:48 | $13.95 | 1,199 | $$17K | SELL |
| 19:18:37 | $13.97 | 2,000 | $$28K | SELL |
| 15:14:34 | $13.77 | 1,123 | $$15K | MIDPOINT |
| 21:00:55 | $13.47 | 1,034 | $$14K | SELL |
5 dark pool trades shown · $$131K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Anika Therapeutics, Inc. (ANIK) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ANIK — frequently asked questions
What is ANIK stock price today?
Anika Therapeutics, Inc. (ANIK) is at $13.81, down 1.00% (-$0.14) at the Nov 12, 2026 close.
Why is ANIK stock moving today?
Latest ANIK news — Nov 7, 2026: Anika Therapeutics lifts 2026 outlook after Q3 2026 report · Nov 6, 2026: Anika Therapeutics holds Q3 2026 earnings call
Why did ANIK stock move on Nov 6, 2026?
Anika Therapeutics reported third-quarter 2026 results, posting adjusted earnings of $0.29 per share, well above the $0.06 consensus, and revenue of $30.594 million that topped the $29.436 million estimate. The company also raised its full-year 2026 sales guidance to a range of $119.588 million to $124.101 million, compared with an analyst estimate of $121.639 million.
What is the ANIK price target?
The average analyst price target for ANIK is $22.00, ranging from $21 to $23, based on 2 analysts.
What do analysts rate ANIK?
Analyst ratings for ANIK: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did ANIK beat earnings?
ANIK last reported on Nov 6, 2026: EPS $0.29 vs $0.42 expected — a miss of 31.0%.
Does ANIK pay a dividend?
ANIK does not currently pay a dividend.
What are ANIK support and resistance levels?
Support: $13.33, $11.92, $9.88. Resistance: $14.58, $16.27, $18.11.
What are insiders doing with ANIK?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on ANIK?
Nov 7, 2026: Anika Therapeutics lifts 2026 outlook after Q3 2026 report · Nov 6, 2026: Anika Therapeutics holds Q3 2026 earnings call · Nov 6, 2026: Anika Therapeutics, Inc. filed a report on a major company event (Form 8-K)